Description
Olsalazine is a prodrug of 5-aminosalicylate that exhibits anti-inflammatory and chemopreventive activities. Olsalazine is used in both human and veterinary medicine and most commonly treats ulcerative colitis. Olsalazine acts as a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2. In colonic epithelial cells, this compound prevents binding of IFN-γ to its receptor and, in other cellular models, inhibits activity of myeloperoxidase. In subjects with ulcerative colitis, olsalazine decreases risk of dysplasia and colorectal cancer.
References
Malewska K, Rychlik A, Nieradka R, et al. Treatment of inflammatory bowel disease (IBD) in dogs and cats. Pol J Vet Sci. 2011;14(1):165-71. PMID: 21528730.
Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov;4(11):1346-50. PMID: 17059900.
Crotty B, Rosenberg WM, Aronson JK, et al. Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. Gut. 1992 Oct;33(10):1353-7. PMID: 1446859.
Kettle AJ, Winterbourn CC. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol. 1991 May 15;41(10):1485-92. PMID: 1850278.
